Overview

A Dose-Ranging Study of ATI 7505 in Patients With Postprandial Distress Syndrome

Status:
Terminated
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy of 3 oral dosing regimens of ATI 7505 compared to placebo in patients with PDS by comparing at the end of Day 42 the percentage of patients in each treatment group who have had adequate relief of postprandial distress syndrome symptoms on at least 50% of the treatment days.
Phase:
Phase 2
Details
Lead Sponsor:
Procter and Gamble
Collaborator:
ARYx Therapeutics
Treatments:
ATI 7505